drugset
drugset / Trial / NCT02153476

A Safety And Efficacy Study Of Alg-1001 In Human Subjects With Symptomatic Focal Vitreomacular Adhesion

NCT02153476 ↗

Phase 2 Completed 45 enrolled Allegro Ophthalmics, LLC
RandomizedParallel-groupQuadruple-blindTreatment

Summary

Evaluate the safety and efficacy of ophthalmic intravitreal injection of ALG-1001 in human subjects with symptomatic focal vitreomacular adhesion

Timeline

Start
2014-02
Primary completion
2015-06
Completion
2015-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Risuteganib Protein / enzyme biologic 2 mg Intravitreal

Indications

vitreous detachment